These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

643 related items for PubMed ID: 25248569

  • 1. Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia.
    Awan Z, Baass A, Genest J.
    Clin Chem; 2014 Nov; 60(11):1380-9. PubMed ID: 25248569
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. PCSK9: a key modulator of cardiovascular health.
    Seidah NG, Awan Z, Chrétien M, Mbikay M.
    Circ Res; 2014 Mar 14; 114(6):1022-36. PubMed ID: 24625727
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. PCSK9: From discovery to therapeutic applications.
    Farnier M.
    Arch Cardiovasc Dis; 2014 Jan 14; 107(1):58-66. PubMed ID: 24373748
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J, Bogsrud MP, Tveten K, Strøm TB, Holven K, Berge KE, Leren TP.
    Transl Res; 2012 Aug 14; 160(2):125-30. PubMed ID: 22683370
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. PCSK9 inhibitors.
    Gencer B, Lambert G, Mach F.
    Swiss Med Wkly; 2015 Aug 14; 145():w14094. PubMed ID: 25856746
    [Abstract] [Full Text] [Related]

  • 16. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.
    Tibolla G, Norata GD, Artali R, Meneghetti F, Catapano AL.
    Nutr Metab Cardiovasc Dis; 2011 Nov 14; 21(11):835-43. PubMed ID: 21943799
    [Abstract] [Full Text] [Related]

  • 17. Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.
    Lipari MT, Li W, Moran P, Kong-Beltran M, Sai T, Lai J, Lin SJ, Kolumam G, Zavala-Solorio J, Izrael-Tomasevic A, Arnott D, Wang J, Peterson AS, Kirchhofer D.
    J Biol Chem; 2012 Dec 21; 287(52):43482-91. PubMed ID: 23135270
    [Abstract] [Full Text] [Related]

  • 18. The contribution of PCSK9 levels to the phenotypic severity of familial hypercholesterolemia is independent of LDL receptor genotype.
    Drouin-Chartier JP, Tremblay AJ, Hogue JC, Ooi TC, Lamarche B, Couture P.
    Metabolism; 2015 Nov 21; 64(11):1541-7. PubMed ID: 26371983
    [Abstract] [Full Text] [Related]

  • 19. The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.
    Poirier S, Mayer G.
    Drug Des Devel Ther; 2013 Nov 21; 7():1135-48. PubMed ID: 24115837
    [Abstract] [Full Text] [Related]

  • 20. Characterisation of de novo mutations in the C-terminal domain of proprotein convertase subtilisin/kexin type 9.
    Geschwindner S, Andersson GM, Beisel HG, Breuer S, Hallberg C, Kihlberg BM, Lindqvist AM, O'Mahony G, Plowright AT, Raubacher F, Knecht W.
    Protein Eng Des Sel; 2015 May 21; 28(5):117-25. PubMed ID: 25744035
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.